# REFLOW Study, Investigating the Efficacy of the LEGFLOW DCB in TASC C&D Fempop Lesions

Study · id `cardio:ct-nct02580955` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02580955](<https://clinicaltrials.gov/study/NCT02580955>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02580955

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 120 participants.

## Technical summary

Registry record NCT02580955. Allocation not applicable; no masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2019-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 120 participants (enrolled count; ClinicalTrials.gov record NCT02580955, source copy `cardio:ctgov-nct02580955-2018-08-13`, retrieved 2026-10-31)
- Start date: 2015-10 (registry gives no type) (ClinicalTrials.gov record NCT02580955, source copy `cardio:ctgov-nct02580955-2018-08-13`, retrieved 2026-10-31)
- Primary completion: 2019-01 (anticipated) (ClinicalTrials.gov record NCT02580955, source copy `cardio:ctgov-nct02580955-2018-08-13`, retrieved 2026-10-31)
- Completion: 2019-01 (anticipated) (ClinicalTrials.gov record NCT02580955, source copy `cardio:ctgov-nct02580955-2018-08-13`, retrieved 2026-10-31)
- Countries: Belgium (ClinicalTrials.gov record NCT02580955, source copy `cardio:ctgov-nct02580955-2018-08-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02580955-2018-08-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: REFLOW Study, Investigating the Efficacy of the LEGFLOW DCB in TASC C&D Fempop Lesions
- Condition: Peripheral Arterial Disease
- Intervention (Device): LEGFLOW DCB
- Lead sponsor: Flanders Medical Research Program
- Lead sponsor class: NETWORK

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Flanders Medical Research Program (`cardio:org-flanders-medical-research-program`)

## Provenance

Content hash: c57bf4a75ff22c3765d66e0cd966447badd1ef34e5aeb4bbf36b8aeda416d096
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
